Pfizer, Roche, Lilly COVID treatments get draft recommendation from UK NHS advisors
Joe Raedle         

The UK's National Institute for Health and Care Excellence ("NICE") has recommended COVID treatments from Pfizer (NYSE:PFE), Roche (OTCQX:RHHBY), and Eli LillyÂ (NYSE:LLY) in draft guidance.
The medications are Pfizer's Paxlovid (nirmatrelvir and ritonavir), Roche's (OTCQX:RHHBF)Â RoActemra (tocilizumab), and Lilly's (LLY) Olumiant (baricitinib).
However, the advisory panel did not recommend Merck's Lagevrio (molnupiravir), Gilead Sciences' (NASDAQ:GILD) Veklury (remdesivir), AstraZeneca's (AZN) Evusheld (tixagevimab and cilgavimab),Â Regeneron Pharmaceuticals (REGN) REGEN-COV (casirivimab and imdevimab), or GlaxoSmithKline (GSK)/Vir Biotechnology's (VIR) Xevudy (sotrovimab).
Earlier in November, Pfizer's (PFE) updated bivalent booster shot won UK regulator authorization.